Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia
| Class:Id | LiteratureReference:9699271 |
|---|
| _displayName | Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia |
|---|
| _timestamp | 2020-09-14 12:16:41 |
|---|
| author | [Person:9699272] Baker, Sharyn D
[Person:9699274] Zimmerman, Eric I
[Person:9699262] Wang, Yong-Dong
[Person:9699268] Orwick, Shelley
[Person:9699265] Zatechka, Douglas S
[Person:9699266] Buaboonnam, Jassada
[Person:9699264] Neale, Geoffrey A
[Person:9699263] Olsen, Scott R
[Person:9699267] Enemark, Eric J
[Person:6802153] Shurtleff, Sheila
[Person:9699273] Rubnitz, Jeffrey E
[Person:6802138] Mullighan, Charles G
[Person:9699269] Inaba, Hiroto |
|---|
| created | [InstanceEdit:9699270] Rothfels, Karen, 2020-09-14 |
|---|
| journal | Clin. Cancer Res. |
|---|
| pages | 5758-68 |
|---|
| pubMedIdentifier | 23969938 |
|---|
| title | Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia |
|---|
| volume | 19 |
|---|
| year | 2013 |
|---|
| (literatureReference) | [DefinedSet:9699525] quizartinib-resistant FLT3 mutants [plasma membrane] [Homo sapiens]
[DefinedSet:9699528] sunitinib-resistant FLT3 mutants [plasma membrane] [Homo sapiens]
[DefinedSet:9699529] midostaurin-sensitive FLT3 mutants [plasma membrane] [Homo sapiens]
[DefinedSet:9699530] sorafenib-resistant FLT3 mutants [plasma membrane] [Homo sapiens]
[DefinedSet:9699532] sunitinib-sensitive FLT3 mutants [plasma membrane] [Homo sapiens]
[DefinedSet:9699536] midostaurin-resistant FLT3 mutants [plasma membrane] [Homo sapiens]
[Reaction:9702508] FLT mutants bind type I TKIs [Homo sapiens]
[FailedReaction:9702601] midostaurin-resistant FLT3 mutants don't bind midostaurin [Homo sapiens]
[FailedReaction:9702618] quizartinib-resistant FLT3 mutants don't bind quizartinib [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia (9699271)
